Collaboration profit (loss) sharing

No definition available.

Name:	biib_Collaborationprofitlosssharing
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Global Licensing Collaboration Agreement, Amount, Shares Purchased

+ References

No definition available.

+ Details

Name:	biib_GlobalLicensingCollaborationAgreementAmountSharesPurchased
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Global Licensing Collaboration Agreement, Purchase Price Per Share

+ References

No definition available.

+ Details

Name:	biib_GlobalLicensingCollaborationAgreementPurchasePricePerShare
Namespace Prefix:	biib_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Global Licensing Collaboration Agreement, Research, Development, Regulatory and Commercial Milestone Payments

+ References

No definition available.

+ Details

Name:	biib_GlobalLicensingCollaborationAgreementResearchDevelopmentRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Global Licensing Collaboration Agreement, Shares, Purchased

+ References

No definition available.

+ Details

Name:	biib_GlobalLicensingCollaborationAgreementSharesPurchased
Namespace Prefix:	biib_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future milestone payments commitment to third party approximately.

+ References

No definition available.

+ Details

Name:	biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Share Of Net Profit From Sage Therapeutics, Percent

+ References

No definition available.

+ Details

Name:	biib_ShareOfNetProfitFromSageTherapeuticsPercent
Namespace Prefix:	biib_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Total upfront and milestone payments made to collaborative partner.

+ References

No definition available.

+ Details

Name:	biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative and Other Relationships - Other Arrangements (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended				3 Months Ended	12 Months Ended
	Aug. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Apr. 30, 2020	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Collaborative arrangements and non-collaborative arrangement transactions
Potential future milestone payments commitment to third party approximately					$ 5,100.0	$ 5,100.0
Share of net profit from sage therapeutics, percent					50.00%	50.00%
Research and development						$ 2,462.0	$ 2,231.1	$ 2,501.2
Sage Therapeutics
Collaborative arrangements and non-collaborative arrangement transactions
Global licensing collaboration, shares purchased, amount		$ 650.0
Global licensing collaboration, shares purchased (in shares)		6.2
Global licensing collaboration, purchase price per share (in dollars per share)		$ 104.14
Global licensing collaboration, development and commercial milestone payments		$ 1,600.0
Research and development expense asset acquired					$ 75.0
Collaboration profit (loss) sharing						4.7
Denali Therapeutics
Collaborative arrangements and non-collaborative arrangement transactions
Global licensing collaboration, shares purchased, amount			$ 465.0
Global licensing collaboration, shares purchased (in shares)			13.0
Global licensing collaboration, purchase price per share (in dollars per share)			$ 34.94
Global licensing collaboration, development and commercial milestone payments			$ 1,100.0
Sangamo Therapeutics, Inc. Agreement
Collaborative arrangements and non-collaborative arrangement transactions
Global licensing collaboration, shares purchased, amount				$ 225.0
Global licensing collaboration, shares purchased (in shares)				24.0
Global licensing collaboration, purchase price per share (in dollars per share)				$ 9.21
InnoCare Pharma Limited (InnoCare) Agreement
Collaborative arrangements and non-collaborative arrangement transactions
Upfront and milestone payments made to collaborative partner	$ 125.0
Other research and discovery
Collaborative arrangements and non-collaborative arrangement transactions
Research and development						$ 4.1	$ 39.2	$ 89.1